纳斯达克上市不足六个月,马来西亚Alps Group调整战略,旨在弥合生物技术可及性差距
该公司正向保险和教育领域扩张,以重塑估值,并让更多人能够获得先进疗法
DeeperDive is a beta AI feature. Refer to full articles for the facts.
本文由AI辅助翻译
【吉隆坡】在纳斯达克上市不到六个月,马来西亚的Alps Group正将其重心从研发转向执行,向保险和教育领域扩张,力求弥合在获取先进医疗技术方面的关键差距。
在Alps努力构建全栈生态系统的同时,它也在应对作为一家新上市生物技术公司所面临的现实挑战。
根据美国证券交易委员会(SEC)的文件和纳斯达克数据显示,Alps Group正处于商业化的早期阶段,其过去12个月的营收约为370万美元,且尚未实现盈利。
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Middle East-linked energy supply shocks put Asean Power Grid back in focus
From intern to C-suite: JPMorgan’s Teresa Heitsenrether on building a fully AI-powered ‘megabank’
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
Prime Orchard condo High Point takes fifth stab at en bloc sale with S$580 million asking price
